Covenant Partners’s AstraZeneca AZN Stock Holding History

Covenant Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,623	Closed	-$850K	–	14
2025 Q4	$850K	Hold	4,623	–	–	0.25%	40
2025 Q3	$709K	Hold	4,623	–	–	0.2%	51
2025 Q2	$646K	Sell	4,623 -547	-11%	-$76.7K	0.19%	58
2025 Q1	$760K	Hold	5,170	–	–	0.25%	49
2024 Q4	$677K	Sell	5,170 -1,793	-26%	-$251K	0.21%	61
2024 Q3	$1.08M	Buy	6,963 +1	+0%	+$161	0.32%	43
2024 Q2	$1.09M	Buy	6,962 +1,093	+19%	+$164K	0.33%	42
2024 Q1	$795K	Buy	5,869 +17	+0.3%	+$2.25K	0.23%	59
2023 Q4	$788K	Sell	5,852 -2,463	-30%	-$320K	0.25%	62
2023 Q3	$1.13M	Sell	8,315 -1,601	-16%	-$219K	0.41%	33
2023 Q2	$1.42M	Sell	9,916 -1,360	-12%	-$200K	0.51%	21
2023 Q1	$1.57M	Sell	11,276 -23	-0.2%	-$3.09K	0.6%	17
2022 Q4	$1.53M	Hold	11,299	–	–	0.62%	19
2022 Q3	$1.24M	Buy	11,299 +5,312	+89%	+$674K	0.6%	22
2022 Q2	$791K	Hold	5,987	–	–	0.37%	53
2022 Q1	$794K	Buy	5,987 +1,219	+26%	+$146K	0.32%	62
2021 Q4	$555K	Hold	4,768	–	–	0.21%	108
2021 Q3	$573K	Buy	+4,768	New	+$555K	0.23%	99
2020 Q3	–	Sell	-4,016	Closed	-$425K	–	195
2020 Q2	$425K	Sell	4,016 -1,644	-29%	-$170K	0.2%	121
2020 Q1	$506K	Sell	5,660 -3,924	-41%	-$369K	0.27%	82
2019 Q4	$956K	Sell	9,584 -2,520	-21%	-$237K	0.45%	44
2019 Q3	$1.08M	Buy	12,104 +2,520	+26%	+$219K	0.57%	35
2019 Q2	$791K	Buy	9,584 +886	+10%	+$69.5K	0.42%	50
2019 Q1	$703K	Buy	+8,698	New	+$686K	0.39%	55

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Covenant Partners's AZN Position: Q1 2026 in Review

Covenant Partners sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 4,623 shares — an estimated $850K sold.

Covenant Partners first reported a position in AZN in Q1 2019 and held it in 24 quarters. The position peaked at $1.57M in Q1 2023. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Covenant Partners reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Covenant Partners sold 4,623 AstraZeneca shares in Q1 2026, an estimated $850K.
Covenant Partners first reported a position in AstraZeneca in Q1 2019 and held it in 24 quarters.
Covenant Partners's AstraZeneca position peaked at $1.57M in Q1 2023.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Covenant Partners's 13F filing for Q1 2026.